| Title |
Urothelial carcinoma: the evolving landscape of immunotherapy for patients with advanced disease
|
|---|---|
| Published in |
Research and Reports in Urology, January 2018
|
| DOI | 10.2147/rru.s125635 |
| Pubmed ID | |
| Authors |
Brian Dietrich, Sandy Srinivas |
| Abstract |
Urothelial carcinoma is the sixth most common malignancy in the US. While most patients present with non-muscle-invasive disease, many will develop recurrent disease including some progressing to muscle invasive metastatic cancer. Treatment outcomes have remained poor and stagnant for those with more advanced illness, with typical 5-year survival rates in the range of ≤15%. While first-line, platinum-based chemotherapy remains the current standard for those eligible, the recent incorporation of checkpoint inhibitors into the management of advanced bladder cancer has resulted in an expansion of treatment options for a difficult-to-treat disease. This review will discuss the historic standard treatment options, followed by the more recent evolving role immune therapy has in the management of bladder cancer. |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 2 | 50% |
| Unknown | 2 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 75% |
| Practitioners (doctors, other healthcare professionals) | 1 | 25% |
Mendeley readers
The data shown below were compiled from readership statistics for 60 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 60 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 11 | 18% |
| Researcher | 8 | 13% |
| Student > Bachelor | 6 | 10% |
| Student > Master | 6 | 10% |
| Student > Ph. D. Student | 4 | 7% |
| Other | 5 | 8% |
| Unknown | 20 | 33% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 19 | 32% |
| Biochemistry, Genetics and Molecular Biology | 7 | 12% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 7% |
| Agricultural and Biological Sciences | 3 | 5% |
| Energy | 1 | 2% |
| Other | 3 | 5% |
| Unknown | 23 | 38% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 February 2018.
All research outputs
#13,578,918
of 23,018,998 outputs
Outputs from Research and Reports in Urology
#100
of 228 outputs
Outputs of similar age
#220,048
of 442,354 outputs
Outputs of similar age from Research and Reports in Urology
#3
of 5 outputs
Altmetric has tracked 23,018,998 research outputs across all sources so far. This one is in the 39th percentile – i.e., 39% of other outputs scored the same or lower than it.
So far Altmetric has tracked 228 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.9. This one has gotten more attention than average, scoring higher than 51% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 442,354 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 48th percentile – i.e., 48% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 5 others from the same source and published within six weeks on either side of this one. This one has scored higher than 2 of them.